Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.37 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491247 | 0.92 | ALOX5AP (0.38) | GLP1RF2RL3ALOX5APHPGDSLC16A3 | |
| SCHEMBL6300962 | 0.90 | ALOX5AP (0.41) | GLP1RF2RL3ALOX5APHPGDKCNH2 | |
| SCHEMBL6299153 | 0.89 | ALOX5AP (0.41) | GLP1RALOX5APHPGDKCNH2SLC16A3 | |
| SCHEMBL6492718 | 0.86 | KDM4E (0.39) | GLP1RALOX5APHPGDKCNH2 | |
| SCHEMBL6494971 | 0.86 | HPGD (0.38) | F2RL3ALOX5APHPGDKCNH2SLC16A3 | |
| SCHEMBL6502298 | 0.86 | PPARG (0.43) | ALOX5APHPGD | |
| SCHEMBL6492587 | 0.85 | PPARG (0.46) | — | |
| SCHEMBL6501797 | 0.85 | DHODH (0.39) | GLP1RALOX5APHPGDKCNH2EDNRB | |
| SCHEMBL6501016 | 0.83 | THRB (0.40) | GLP1RALOX5APHPGD | |
| SCHEMBL6298703 | 0.81 | ALOX5AP (0.40) | ALOX5APHPGDSLC16A3SLC16A1MCTS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | GLP1R 62/4885F2RL3 3940/4885ALOX5AP 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.